NAVB News and Press, Navidea Biopharmaceuticals Inc. From 03/31/23

2023-03-31 05:00:30 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said Michael Rosol stepped down as chief medical officer and the company has hired G2G Ventures as executive consultants to help with its growth plans. The company noted that the chief medical officer's ...

Executive Consulting buttresses senior management’s focus on performance and targeted growth. Chief Medical Officer, Michael Rosol, Ph.D., steps down. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focuse...

2023-03-21 22:44:05 ET Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Conference Call March 22, 2023, 17:00 ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Administration and Principal Financial & A...

2023-03-21 16:04:50 ET Navidea Biopharm press release ( NYSE: NAVB ): Q4 GAAP EPS of -$0.11. Total revenues for the three-month period ended December 31, 2022 were approximately $1,000, compared to $50,000 for the same period in 2021. Navidea ended the fourth quarter o...

Conference Call to be held Tuesday, March 21, 2023 at 5:00 pm (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today an...

2023-03-20 17:35:07 ET Major earnings expected after the bell on Tuesday include: NIKE ( NKE ) GameStop ( GME ) Array Technologies ( ARRY ) AAR Corp. ( AIR ) HealthEquity ( HQY ) For further details see: Notable earnings after Tuesday's close

Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, tod...

Navidea Biopharmaceuticals ( NYSE: NAVB ) stock rose ~25% after the company said it received a notice of allowance from the U.S. Patent and Trademark Office covering a key component of the company's cancer immunotherapy pipeline. The patent application is titled, 'Composi...

Targeted therapeutics designed to alter the behavior of macrophages to rally the body’s immune response against tumors Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precisio...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary M...